Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abilify as Adjunctive Treatment for Refractory Unipolar Depression
NCT00220636Phase 4Completed
- Sponsor
- St. Luke's-Roosevelt Hospital Center
- Start
- Mar 2005
- Primary completion
- Mar 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of aripiprazole in major depressive disorder (MDD), sponsored by St. Luke's-Roosevelt Hospital Center. Primary endpoint: Hamilton Depression Rating Scale at 12 weeks. Started Mar 2005; status: completed.
02
Drugs
aripiprazole
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00220636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00220636.